(IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback